Bank of New York Mellon’s Champions Oncology CSBR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $133K | Hold |
21,614
| – | – | ﹤0.01% | 4181 |
|
|
2026
Q1 | $124K | Sell |
21,614
-5,135
| -19% | -$32.6K | ﹤0.01% | 4077 |
|
|
2025
Q4 | $185K | Hold |
26,749
| – | – | ﹤0.01% | 4046 |
|
|
2025
Q3 | $173K | Hold |
26,749
| – | – | ﹤0.01% | 4049 |
|
|
2025
Q2 | $197K | Hold |
26,749
| – | – | ﹤0.01% | 3992 |
|
|
2025
Q1 | $232K | Hold |
26,749
| – | – | ﹤0.01% | 3822 |
|
|
2024
Q4 | $229K | Hold |
26,749
| – | – | ﹤0.01% | 3902 |
|
|
2024
Q3 | $130K | Hold |
26,749
| – | – | ﹤0.01% | 3980 |
|
|
2024
Q2 | $138K | Hold |
26,749
| – | – | ﹤0.01% | 3999 |
|
|
2024
Q1 | $131K | Sell |
26,749
-4,026
| -13% | -$23.6K | ﹤0.01% | 4004 |
|
|
2023
Q4 | $173K | Hold |
30,775
| – | – | ﹤0.01% | 3990 |
|
|
2023
Q3 | $191K | Hold |
30,775
| – | – | ﹤0.01% | 3968 |
|
|
2023
Q2 | $196K | Hold |
30,775
| – | – | ﹤0.01% | 3978 |
|
|
2023
Q1 | $124K | Hold |
30,775
| – | – | ﹤0.01% | 4040 |
|
|
2022
Q4 | $139K | Hold |
30,775
| – | – | ﹤0.01% | 4071 |
|
|
2022
Q3 | $231K | Hold |
30,775
| – | – | ﹤0.01% | 3955 |
|
|
2022
Q2 | $246K | Hold |
30,775
| – | – | ﹤0.01% | 3975 |
|
|
2022
Q1 | $250K | Hold |
30,775
| – | – | ﹤0.01% | 4117 |
|
|
2021
Q4 | $257K | Hold |
30,775
| – | – | ﹤0.01% | 4158 |
|
|
2021
Q3 | $314K | Sell |
30,775
-21,050
| -41% | -$214K | ﹤0.01% | 4017 |
|
|
2021
Q2 | $533K | Sell |
51,825
-16,424
| -24% | -$167K | ﹤0.01% | 3740 |
|
|
2021
Q1 | $772K | Sell |
68,249
-490
| -0.7% | -$5.69K | ﹤0.01% | 3475 |
|
|
2020
Q4 | $741K | Sell |
68,739
-754
| -1% | -$7.78K | ﹤0.01% | 3420 |
|
|
2020
Q3 | $642K | Hold |
69,493
| – | – | ﹤0.01% | 3366 |
|
|
2020
Q2 | $664K | Buy |
69,493
+17,178
| +33% | +$146K | ﹤0.01% | 3325 |
|
|
2020
Q1 | $387K | Hold |
52,315
| – | – | ﹤0.01% | 3492 |
|
|
2019
Q4 | $436K | Hold |
52,315
| – | – | ﹤0.01% | 3651 |
|
|
2019
Q3 | $295K | Hold |
52,315
| – | – | ﹤0.01% | 3782 |
|
|
2019
Q2 | $409K | Hold |
52,315
| – | – | ﹤0.01% | 3696 |
|
|
2019
Q1 | $512K | Sell |
52,315
-164
| -0.3% | -$1.63K | ﹤0.01% | 3538 |
|
|
2018
Q4 | $409K | Buy |
+52,479
| New | +$603K | ﹤0.01% | 3586 |
|
Other funds holding CSBR
MFIM
CCWM
SS
Bank of New York Mellon's CSBR Position: Q2 2026 in Review
Bank of New York Mellon held its Champions Oncology (CSBR) position steady in Q2 2026 at 21,614 shares worth $133K. The position accounts for ﹤0.01% of the portfolio, ranked #4181.
Bank of New York Mellon first reported a position in CSBR in Q4 2018 and has held it in 31 quarters since. The position peaked at $772K in Q1 2021. 9 funds tracked by Wall St. Rank hold CSBR as of Q2 2026.
- Bank of New York Mellon held 21,614 shares of Champions Oncology worth $133K as of Q2 2026.
- Bank of New York Mellon left its Champions Oncology share count unchanged in Q2 2026.
- Champions Oncology made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #4181 holding.
- Bank of New York Mellon first reported a position in Champions Oncology in Q4 2018 and has held it in 31 quarters since.
- Bank of New York Mellon's Champions Oncology position peaked at $772K in Q1 2021.
- 9 funds tracked by Wall St. Rank held Champions Oncology as of Q2 2026.
Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.